TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02351115
Drug: B=Inhaled Alprazolam 0.5 mg
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02351115
Drug: C=Inhaled Alprazolam 1 m
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02351115
Drug: D= Inhaled Alprazolam 2 mg
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03932526
Drug: Vinorelbine + placebo
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
Study: NCT03932526
Drug: Vinorelbine + Apatinib
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
Study: NCT02717091
Drug: gemcitabine + nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01384539
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01384539
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01645709
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03532789
Drug: herbal patch
Normalized name: MENTHOL 5.1 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL PATCH [Lekon Herbal Patch Green]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One patch with medicine should be applied to the skin every other day within two weeks
Study: NCT04249882
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg once a day
Study: NCT04249882
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg twice a day
Study: NCT02176486
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib capsules.
Study: NCT02477384
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00650923
Drug: ziv-aflibercept
Normalized name: Ziv-Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00650923
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00143325
Drug: varenicline (CP-526,555)
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03733652
Drug: Interferon Alfa 2a
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
Study: NCT02862769
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: . Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
Study: NCT02862769
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
Study: NCT00691665
Drug: Olopatadine HCL Nasal Spray, 0.6%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
Study: NCT00691665
Drug: Fluticasone Propionate Nasal Spray, 50 mcg
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
Study: NCT03233035
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
Study: NCT00562419
Drug: CT-322
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV solution, weekly
Study: NCT00562419
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV solution, biweekly
Study: NCT00552266
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets 10-60 mg/day administered once or twice daily 6 weeks
Study: NCT01392833
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
Study: NCT01392833
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
Study: NCT02216565
Drug: Alteplase if patient is eligible
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
Study: NCT01814657
Drug: Lidocaine hydrochloride (HCl) 1% solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
Study: NCT00024622
Drug: O-15 Water
Normalized name: water, O-15
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01884298
Drug: epidural infusing 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
Study: NCT01470027
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 900mg NAC effervescent tablets
Study: NCT04558697
Drug: Tea tree oil vagitories
DrugBank: Tea tree oil (DB11218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea tree oil vagitories will be administered once daily for 5 days
Study: NCT03578679
Drug: Ivermectin Oral Product
Normalized name: ivermectin Oral Product
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of pediculosis (head lice)
Study: NCT04049825
Drug: OPB-111077
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-111077+bendamustine
Study: NCT04049825
Drug: OPB-111077
Normalized name: OPB-111077
DrugBank: OPB-111077 (DB16630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-111077+rituximab+bendamustine
Study: NCT01755169
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
Study: NCT00304473
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00527202
Drug: botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin A versus saline in parallel groups
Study: NCT03882918
Drug: OV101
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
Study: NCT00098787
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00098787
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00864734
Drug: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
Normalized name: glyburide / metformin hydrochloride Oral Tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
Study: NCT00643149
Drug: amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
Study: NCT00201539
Drug: single dose Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00201539
Drug: double dose Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02388321
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
Study: NCT00503399
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 µg/day sc for 18 months
Study: NCT00503399
Drug: Risedronate
Normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg/week po for 18 months
Study: NCT00768560
Drug: Nifedipine (Adalat CR, BAYA1040) 80mg OD
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
Study: NCT00768560
Drug: Nifedipine (Adalat CR, BAYA1040) 40mg BID
Normalized name: nifedipine 40 MG
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
Study: NCT00768560
Drug: Nifedipine (Adalat CR, BAYA1040) 40mg OD
Normalized name: nifedipine 40 MG
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
Study: NCT00597649
Drug: Bicifadine
Normalized name: Bicifadine
DrugBank: Bicifadine (DB04889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR dosage form of 400 mg bid or tid for one year
Study: NCT01636557
Drug: Sirukumab
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
Study: NCT01636557
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study: NCT01636557
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study: NCT01636557
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study: NCT01636557
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
Study: NCT01311778
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.
Study: NCT01298063
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 tablet, once qd in the morning
Study: NCT00002684
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002684
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002684
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03632161
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
Study: NCT03632161
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isobaric bupivacaine 0.5% (0.3ml/kg)
Study: NCT01592630
Drug: 0.2% ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
Study: NCT01592630
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-Q pumps containing saline to be attached to TAP catheters
Study: NCT03503942
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
Study: NCT00418171
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00418171
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01128387
Drug: Panitumumab
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
Study: NCT03427073
Drug: ALM201
Normalized name: ALM201
DrugBank: ALM201 (DB17206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: ALM201 administered subcutaneously
Study: NCT01467323
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injected subcutaneously (under the skin) twice daily
Study: NCT01467323
Drug: biphasic human insulin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injected subcutaneously (under the skin) twice daily
Study: NCT01660815
Drug: florbetapir (18F)
Normalized name: florbetapir (18F)
DrugBank: Florbetapir F-18 (DB09149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV injection, 370 MBq (10mCi), single dose
Study: NCT00005912
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03140826
Drug: meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics to treat infections.
Study: NCT00257634
Drug: dexamethasone to injury site
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02955329
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will vape tobacco leaves with nicotine out of the PAX device.
Study: NCT02955329
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will vape marijuana leaves with nicotine out of the PAX device.
Study: NCT00175305
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00343902
Drug: Crataegus Special Extract WS 1442
Normalized name: crataegus extract
DrugBank: Hawthorn leaf with flower (DB15839)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01989663
Drug: 1% vaginally applied tenofovir gel
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01949519
Drug: Lycopene and Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
Study: NCT01989663
Drug: Tenofovir film- 10mg
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01989663
Drug: Tenofovir Film-40 mg
Normalized name: tenofovir disoproxil
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00632580
Drug: intraarticular injection with ropivacaine
Normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00632580
Drug: extraarticular injection with ropivacaine
Normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03860506
Drug: PSI-697
Normalized name: PSI-697
DrugBank: PSI-697 (DB12211)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02700529
Drug: ubenimex
Normalized name: Ubenimex
DrugBank: Ubenimex (DB03424)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00743795
Drug: GS-9190
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg oral BID
Study: NCT00743795
Drug: Peginterferon Alfa 2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
Study: NCT00743795
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
Study: NCT01126229
Drug: Low dose Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
Study: NCT01126229
Drug: High dose Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
Study: NCT00558090
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
Study: NCT02678806
Drug: Postoperative TACE
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 \~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
Study: NCT05303740
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study.
Study: NCT00384579
Drug: Botulinum toxin B
Normalized name: botulinum toxin type B
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin B
Study: NCT02658461
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed \>1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
Study: NCT01778244
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000mg/day for 24 weeks
Study: NCT01805648
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
Study: NCT00346827
Drug: Apomorphine Nasal Powder
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049348
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no